liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Clinical characteristics and quality-of-life in patients surviving a decade of prostate cancer with bone metastases
Linköping University, Department of Clinical and Experimental Medicine. Linköping University, Faculty of Medicine and Health Sciences.
Eksatravagen 72, Uppsala, Sweden.
Linköping University, Department of Clinical and Experimental Medicine, Urology. Linköping University, Faculty of Health Sciences. Region Östergötland, Center for Surgery, Orthopaedics and Cancer Treatment, Department of Urology in Östergötland.
Karolinska Institute Solna, Sweden.
Show others and affiliations
2016 (English)In: BJU International, ISSN 1464-4096, E-ISSN 1464-410X, Vol. 117, no 6, 904-913 p.Article in journal (Refereed) PublishedText
Abstract [en]

Objective To describe characteristics and quality-of-life (QoL), and to define factors associated with long-term survival in a subgroup of patients with prostate cancer with M1b disease. Patients and Methods The study was based on 915 patients from a prospective randomised multicentre trial (No. 5) by the Scandinavian Prostate Cancer Group, comparing parenteral oestrogen with total androgen blockade. Long-term survival was defined as patients having an overall survival of >= 10 years, and logistic regression models were constructed to identity clinical predictors of survival. QoL during follow-up was assessed using the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire - C30 version 1 (EORTC-C30) ratings. Results In all, 40 (4.4%) of the 915 men survived for >10 years. Factors significantly associated with increased likelihood of surviving for >10 years in the univariate analyses were: absence of cancer-related pain; Eastern Cooperative Oncology Group (ECOG) performance status of <2; negligible analgesic consumption; T-category of 1-2; prostate-specific antigen (PSA) level of <231 mu g/L; and a Soloway score of 1. In the multivariate analyses, ECOG performance status of <2, PSA level of <231 mu g/L, and Soloway score of 1, were all independent predictors of long-term survival. All subscales of the EORTC-C30 were higher in this group than for patients with short survival, but slowly declined over the decade. Conclusion A subgroup of patients with prostate cancer with M1b disease and certain characteristics showed a positive long-term response to androgen-deprivation therapy with an acceptable QoL over a decade or more. Independent predictors of long-term survival were identified as ECOG performance status of <2, limited extent of bone metastases (Soloway score of 1), and a PSA level of <231 mu g/L at the time of enrolment.

Place, publisher, year, edition, pages
WILEY-BLACKWELL , 2016. Vol. 117, no 6, 904-913 p.
Keyword [en]
prostate cancer; bone metastases; long-term survival; quality-of-life
National Category
Clinical Medicine
URN: urn:nbn:se:liu:diva-128927DOI: 10.1111/bju.13190ISI: 000376009800015PubMedID: 26033416OAI: diva2:934980
Available from: 2016-06-09 Created: 2016-06-07 Last updated: 2016-06-09

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Klaff, RamiVarenhorst, Eberhard
By organisation
Department of Clinical and Experimental MedicineFaculty of Medicine and Health SciencesUrologyFaculty of Health SciencesDepartment of Urology in Östergötland
In the same journal
BJU International
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 10 hits
ReferencesLink to record
Permanent link

Direct link